Condition
Spinocerebellar Ataxia 3
Total Trials
6
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Completed3
Unknown2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03408080Phase 3Active Not Recruiting
Open Pilot Trial of BHV-4157
NCT03487367Unknown
Clinical Trial Readiness for SCA1 and SCA3
NCT04153110Not ApplicableCompleted
Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia
NCT04426149Not ApplicableCompletedPrimary
Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3
NCT03120013Not ApplicableCompleted
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
NCT02175290UnknownPrimary
Machado-Joseph Disease in Israel
Showing all 6 trials